SCHEMBL10274716

SCHEMBL10274716

C=C(C)c1cc(Cl)ccc1N1CCN(C(=O)C(=O)OCC)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.52
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
IDE P14735 1/20 0.47
ALDH1A1 P00352 2/20 0.46
MAPT P10636 4/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 1/20 0.43
TSHR P16473 3/20 0.42
AKR1C3 P42330 1/20 0.42
MGLL Q99685 1/20 0.42
USP2 O75604 1/20 0.41
HTT P42858 3/20 0.41
MAPK1 P28482 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL766986 0.88 PKM (0.54) PKMMEN1KMT2AALDH1A1MAPT
SCHEMBL766987 0.84 PKM (0.53) PKMMEN1KMT2AALDH1A1MAPT
SCHEMBL766847 0.84 ALDH1A1 (0.50) PKMMEN1KMT2AALDH1A1MAPT
SCHEMBL630561 0.81 PKM (0.53) PKMMEN1KMT2AIDEALDH1A1
SCHEMBL11129384 0.77 MEN1 (0.62) MEN1KMT2AIDEALDH1A1MAPT
SCHEMBL12631676 0.76 POLB (0.57) PKMMEN1KMT2AALDH1A1MAPT
SCHEMBL631288 0.76 PKM (0.50) PKMMEN1KMT2AALDH1A1MAPT
SCHEMBL10274550 0.74 KMT2A (0.49) MEN1KMT2AALDH1A1MAPTL3MBTL1
SCHEMBL766675 0.73 HTT (0.48) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL630912 0.71 PKM (0.55) PKMMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071489-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071489-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES RBP4, RBP1, FABP4 PKM 3988/4885MEN1 3929/4885KMT2A 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.